Economy

The Karyopharm Therapeutics Inc (KPTI) Receives $14.17 Average Price Target from Analysts

The Karyopharm Therapeutics Inc (KPTI) Receives $14.17 Average Price Target from Analysts”

Karyopharm Therapeutics Inc. has a 12-month low of $6.27 and a 12-month high of $14.63. The stock was sold at an average price of $11.00, for a total transaction of $1,298.00. On average, equities research analysts anticipate that Karyopharm Therapeutics will post ($2.68) EPS for the current fiscal year. The firm has "Buy" rating given on Wednesday, September 9 by Jefferies.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been the object of insider selling activity recently. The rating was upgraded by Jefferies on Tuesday, August 30 to "Buy". After $-0.64 actual earnings per share reported by Karyopharm Therapeutics Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth. They now have a Dollars 42 price target on the stock. Finally, Canaccord Genuity set a $18.00 price target on shares of Karyopharm Therapeutics and gave the company a "buy" rating in a research note on Tuesday, August 8th. Cantor Fitzgerald reiterated an "overweight" rating and set a $18.00 price objective on shares of Karyopharm Therapeutics in a research note on Monday, May 15th. The company was maintained on Wednesday, August 12 by MLV.

Petroleum & Resources Corp increased Exxon Mobil Corp (XOM) stake by 0.33% reported in 2016Q4 SEC filing. Envestnet Asset Mgmt Incorporated has 96 shares for 0% of their portfolio. Bank of New York Mellon Corp now owns 181,602 shares of the company's stock valued at $2,332,000 after purchasing an additional 69,315 shares during the period. About 432,710 shares traded or 146.40% up from the average. The value of the company's investment in Karyopharm Therapeutics Inc. decreased from $3,531,000 to $2,715,000 a change of 23.1% quarter to quarter. The company reported ($0.64) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.64). Karyopharm Therapeutics earned a coverage optimism point of 0.13 on Accern's range. The stock's market capitalization is 498.25M. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It now has negative earnings. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Investors sentiment increased to 1.56 in 2016 Q4. Its up 0.40, from 1.16 in 2016Q3. Endurance Wealth Management Inc. boosted its position in shares of Karyopharm Therapeutics by 166.7% in the third quarter. Barclays Public Ltd Company stated it has 6,266 shares. 102,556 are held by Morgan Stanley. Credit Suisse Ag has 17,859 shares. Karyopharm Therapeutics Inc. had 22 analyst reports since August 11, 2015 according to SRatingsIntel. Vanguard Group Inc. raised its holdings in shares of Karyopharm Therapeutics by 31.1% in the 2nd quarter. 6,994 are held by Blackrock Group.

News articles about Karyopharm Therapeutics (NASDAQ:KPTI) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Zacks Lowered stocks of Karyopharm Therapeutics from a "buy" recommendation to a "hold" recommendation in a study on Tue, Jul 18th. New York State Common Retirement Fund reported 29,430 shares stake. Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. Cam Gru Holdg A S holds 0% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI) for 13,000 shares. Bnp Paribas Arbitrage Sa has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Geode Cap Management Lc has 156,493 shares for 0% of their portfolio. Creative Planning, Kansas-based fund reported 5,700 shares.

The stock increased 3.05% or $0.08 on September 15, reaching $2.7. It has outperformed by 4.49% the S&P500. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Therefore 38% are positive. Robert W. Baird maintained the stock with "Outperform" rating in Friday, April 7 report. The rating was initiated by Macquarie Research with "Underperform" on Wednesday, September 23. A rating of 3 would indicate a Hold recommendation. Goldman Sachs holds 101,702 shares. The rating was initiated by Raymond James on Friday, May 27 with "Outperform". Investors may be watching shares for trading volume that is out of the ordinary. 104 funds opened positions while 652 raised stakes. 4,868 were accumulated by Thomas J Herzfeld Advisors Inc. California-based Elm Advsrs Ltd Liability has invested 0.26% in Exxon Mobil Corporation (NYSE:XOM). Bokf Na accumulated 2.33M shares.



Like this

loading...
loading...

Latest


20 September 2017
Upset New York Giants Fan Hilariously Updates LT Ereck Flowers' Wikipedia Page
As for what the Giants could do to speed up that improvement, McAdoo said everything would be looked at. McAdoo actually did not sound open to any personnel changes at all. "They're not given away".

20 September 2017
Fifth Third Bancorp (FITB) Shares Sold by Axa
Several analysts have released their opinion on Fifth Third Bancorp (NASDAQ: FITB ), with 1 analysts believing it is a strong buy. Fifth Third Bancorp (FITB ) have shown a high EPS growth of 10.30% in the last 5 years and has earnings decline of -4.00% yoy.

20 September 2017
Mercer County continues to lead OH in lowest rate of unemployment
The national unemployment rate, 4.4 percent, was little changed from July but was 0.5 percentage points lower than in August 2016. The unemployment rate stood at 4.5 percent during August across the country and at 4.9 percent statewide.

20 September 2017
Island School's Sullivan is National Merit Scholarship semifinalist
About 15,000 students are expected to move on to become National Merit Finalists, which should be announced in February. Time spent in the library is paying off for a Howell student who is in the running for a distinguished scholarship.

20 September 2017
Two Pak infiltrators shot dead near Punjab border
Taking cover, the fire was appropriately retaliated and infiltrators were neutralised near the Border Security Fence. When challenged by the BSF troops, the infiltrators fired along the ambush line with automatic weapons.

20 September 2017
Top RSI Trades for Today - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Finally, Victory Capital Management Inc. boosted its holdings in Supernus Pharmaceuticals by 17.7% in the second quarter. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock.

20 September 2017
Canterbury Bulldogs sack coach Des Hasler
An assistant to Hasler at the Bulldogs, Jim Dymock has not shied away from the fact that he would like to coach the club in the past.

20 September 2017
Terry Fox Run raises $2400 this past Sunday
More than 100 participants raised over $7,000 in this year's Terry Fox Run in Meaford on Sunday, September 17. Historically, the South Surrey run raises between $10,000-$15,000, Scoffield told PAN last week.

20 September 2017
OnePlus partners Castelbajac to launch OnePlus 5 limited edition on September 22
As of now, there is information about the availability of the OnePlus 5 JCC Limited Edition outside of Europe. It sports a 5.5-inch Optic AMOLED display with Full HD resolution and Corning Gorilla Glass 5 protection.

20 September 2017
Catalent Inc (CTLT) Research Coverage Started at Needham & Company LLC
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link . The deal is in keeping with Catalent Q3 report in May when it said biologics-related contracting had driven earnings growth.